BioArctic AB (publ) (BIOA-B) - Cash Flow Conversion Efficiency
Based on the latest financial reports, BioArctic AB (publ) (BIOA-B) has a cash flow conversion efficiency ratio of -0.076x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-166.00 Million ≈ $-17.86 Million USD) by net assets (Skr2.20 Billion ≈ $236.54 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see BioArctic AB (publ) stock valuation for the company's overall valuation and market capitalisation.
BioArctic AB (publ) - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how BioArctic AB (publ)'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
BioArctic AB (publ) Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BioArctic AB (publ) ranked by their cash flow conversion efficiency. Explore BioArctic AB (publ) cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Peab AB (publ)
ST:PEAB-B
|
-0.049x |
|
Opendoor Technologies Inc
NASDAQ:OPEN
|
0.070x |
|
Hugo Boss AG
XETRA:BOSS
|
0.076x |
|
Chongqing Zongshen Power Machinery Co Ltd
SHE:001696
|
0.021x |
|
Attica Bank S.A.
AT:TATT
|
-0.468x |
|
Hugo Boss AG
F:BOSA
|
0.082x |
|
Silvercorp Metals Inc
TO:SVM
|
0.048x |
|
Hawkins Inc
NASDAQ:HWKN
|
0.071x |
Annual Cash Flow Conversion Efficiency for BioArctic AB (publ) (2015–2025)
The table below shows the annual cash flow conversion efficiency of BioArctic AB (publ) from 2015 to 2025. View BioArctic AB (publ) stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr1.97 Billion ≈ $211.69 Million |
Skr1.43 Billion ≈ $154.01 Million |
0.728x | +305.82% |
| 2024-12-31 | Skr894.94 Million ≈ $96.31 Million |
Skr-316.33 Million ≈ $-34.04 Million |
-0.353x | -219.45% |
| 2023-12-31 | Skr1.05 Billion ≈ $112.63 Million |
Skr309.69 Million ≈ $33.33 Million |
0.296x | +835.38% |
| 2022-12-31 | Skr786.24 Million ≈ $84.61 Million |
Skr-31.64 Million ≈ $-3.40 Million |
-0.040x | +77.41% |
| 2021-12-31 | Skr788.68 Million ≈ $84.87 Million |
Skr-140.46 Million ≈ $-15.12 Million |
-0.178x | -74.98% |
| 2020-12-31 | Skr907.30 Million ≈ $97.64 Million |
Skr-92.34 Million ≈ $-9.94 Million |
-0.102x | -130.32% |
| 2019-12-31 | Skr974.50 Million ≈ $104.87 Million |
Skr327.17 Million ≈ $35.21 Million |
0.336x | +270.79% |
| 2018-12-31 | Skr1.02 Billion ≈ $109.52 Million |
Skr-200.06 Million ≈ $-21.53 Million |
-0.197x | +7.60% |
| 2017-12-31 | Skr636.13 Million ≈ $68.46 Million |
Skr-135.33 Million ≈ $-14.56 Million |
-0.213x | -101.91% |
| 2016-12-31 | Skr60.76 Million ≈ $6.54 Million |
Skr675.13 Million ≈ $72.65 Million |
11.111x | +7421.42% |
| 2015-12-31 | Skr108.28 Million ≈ $11.65 Million |
Skr-16.43 Million ≈ $-1.77 Million |
-0.152x | -- |
About BioArctic AB (publ)
BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden. It engages in the research and development of biological drugs, such as antibodies that address high unmet medical needs. The company's therapeutic areas encompass neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, and other ALS diseases. In addition, it offers L… Read more